Agape ATP vs Mangoceuticals
Agape ATP is the larger business, with $1.5m of revenue in fiscal 2025 against $456,021 for Mangoceuticals (3.3 times as much). Agape ATP grew faster (15.2% against -26.0%). Agape ATP kept more of each dollar of sales as profit: a net margin of -149.6% against -4526.8%. Agape ATP carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Agape ATPATPC, 2025 | MangoceuticalsMGRX, 2025 |
|---|---|---|
| Revenue | $1.5m | $456,021 |
| Revenue growth | 15.2% | -26.0% |
| Net income | −$2.3m | −$20.6m |
| Operating margin | -213.7% | -3954.3% |
| Net margin | -149.6% | -4526.8% |
| Return on equity | -18.7% | -141.6% |
| Free cash flow | −$2.4m | −$5.9m |
| Cash | $89,651 | $1.5m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 18 | — |
| Market value | $1.3m | $3.6m |
| Price vs our value range | — | — |
| Moat score | 33 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 4 sales |